CureVac Appoints Pierre Kemula as Chief Financial Officer

TUBINGEN, Germany, Oct. 11, 2016 /PRNewswire/ -- CureVac AG, the most clinically advanced mRNA company, today announced the appointment of Pierre Kemula as Chief Financial Officer (CFO). Mr. Kemula will join CureVac's management board and will be responsible for leading the company's financial and capital markets activities.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, "Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA."

Mr. Kemula joins CureVac after serving as Chief Financial Officer of Pixium Vision, a medical technology company developing innovative Bionic Vision Systems to provide a form of vision to blind patients suffering from outer retinal degeneration. During his tenure as CFO of Pixium Vision, Mr. Kemula was instrumental in the company's successful initial public offering on Euronext. Prior to Pixium Vision, Mr. Kemula was with Ipsen, a global specialty-driven pharmaceutical company, where he held the position of Vice President Corporate Finance, Treasury and Financial Markets. Mr. Kemula began his career in consulting, with successful tenures at Roland Berger, Kea & Partners, Gemini Consulting and KPMG. He received his degree in Management Sciences from the London School of Economics (LSE) in the United Kingdom.

Mr. Kemula commented, "Since its founding in 2000, CureVac has established itself as the mRNA pioneer, boasting the industry's most advanced clinical pipeline, while securing approximately $330 million in equity investments and forging collaborations with numerous multinational organizations. I welcome the opportunity to join CureVac as its new Chief Financial Officer and look forward to working alongside the team to accelerate CureVac's growth trajectory and drive the company's financial success."

About CureVac AG

Founded in 2000 as a spin-off from the University of Tϋbingen in Germany, CureVac is a technology leader in the development of drugs that are based on the Messenger RNA (mRNA) molecule. The company has an extensive expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac's mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases, molecular therapies designed to trigger the body's own production of therapeutic proteins, and a novel, RNA-based adjuvant therapy designed to enhance the immunogenicity of vaccines and proteins.

CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

For more information, please visit www.curevac.com.

Media Contacts
Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756
[email protected]

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694
[email protected]

SOURCE CureVac AG

Related Links

http://www.curevac.com